TrialESMO open2022

Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer.

R Wuerstlein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.